Anumana ECG-AI LEF

Introducing ECG-AI™ LEF: FDA-Cleared AI Algorithm to Detect Low Left Ventricular Ejection Fraction

Breakthrough Software as a Medical Device (SaMD) to aid clinicians in detecting low ejection fraction (LEF) earlier than ever before

About ECG-AI LEF Patient Impact Clinical Evidence Clinical Workflow Integration

Our Breakthrough FDA-Cleared Algorithm

ECG-AI LEF: FDA cleared AI algorithm to detect low left ventricular ejection fraction

ECG-AI LEF is an algorithm developed in partnership with Mayo Clinic and nference

State-of-the-art deep learning model developed using over 100,000 ECGs and echo data pairs from unique patients

Early versions of ECG-AI LEF Evaluated in 25+ studies involving >40,000 patients in the U.S. and internationally

PHI secure and compliant, and seamlessly integrates into existing clinical workflows

Diagnose Heart Failure Earlier with ECG-AI LEF

Anumana's ECG-AI LEF can detect low EF earlier, without the onset of clear symptoms or conventionally identified ECG abnormalities

Heart failure is a progressive condition affecting over 6 million people in the U.S.¹ Early intervention can improve outcomes, but detection of early heart failure is challenging as patients are often asymptomatic or present non-specific symptoms.² Identification of patients with LEF (EF≤40%) can enable clinicians to intervene earlier and prevent the progression of the disease.³ An echocardiogram, while capable of diagnosing LEF, necessitates a clear indication of cardiac abnormalities for scheduling, often entails extended waiting periods, and demands significant resources, potentially resulting in diagnostic delays.

ECG-AI LEF represents a groundbreaking shift in ECG interpretation. The ECG is a widely utilized and swiftly administered test, used in both primary and specialized healthcare settings. While it generates intricate patterns across its 12 leads, the majority of clinicians and ECG analysis machines are trained to use simple sets of rules to identify signs of disease using ECG. In early heart failure stages, ECG-AI's ability to detect subtle yet complex ECG patterns surpasses those of conventional interpretation standards.

References:

Tsao CW, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147:e93–e621. doi: 10.1161/CIR.0000000000001123.
Attia, Z.I., Kapa, S., Lopez-Jimenez, F. et al. Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram. Nat Med 25, 70–74 (2019). https://doi.org/10.1038/s41591-018-0240-2
Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022 May, 79 (17) e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012

Clinically Proven to Detect LEF

ECG-AI LEF is a highly effective screening tool for identifying low EF and has the potential to uncover significantly more low EF cases than echocardiograms alone

Proprietary AI built on vast real world data

Developed in partnership with Mayo Clinic and nference
Trained on over 100,000 ECG and echo data pairs from unique patients^1,3

FDA Breakthrough Device with rigorous data validation

Recognized as a breakthrough device by the FDA in 2019²
Evaluated in 25+ studies and across multiple institutions in the U.S. and internationally³
Rigorously validated across diverse clinical settings, including inpatient, outpatient, & emergency departments

Robust clinical data across a diverse patient population³

In a multi-site, geographically-diverse, retrospective validation study with 16,000 patients, ECG-AI LEF demonstrated:

	Sensitivity	Specificity
Overall	84.5%	83.6%

EAGLE Study:⁴

22,000+

Patients

120

Primary Care Teams

31% Increase

LEF Detection

In a prospective, randomized, controlled trial of 22,000+ individuals across 120 primary care teams, the investigational version of the ECG-AI LEF demonstrated 31% increase in LEF detection compared to standard of care, without increasing use of echocardiography, where the majority of patients received additional treatments.

Learn more

References:

Attia, Z.I., Kapa, S., Lopez-Jimenez, F. et al. Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram. Nat Med 25, 70–74 (2019). https://doi.org/10.1038/s41591-018-0240-2
Fierce Biotech, https://www.fiercebiotech.com/medtech/mayo-clinic-ai-algorithm-proves-effective-at-spotting-early-stage-heart-disease-routine-ekg
Anumana Data on File
Yao, X., Rushlow, D.R., Inselman, J.W. et al. Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. Nat Med 27, 815–819 (2021). https://doi.org/10.1038/s41591-021-01335-4

Easily Integrated into EHR and Clinical Workflow

Anumana’s ECG-AI LEF solution can be integrated with any ECG information management system or directly with any institution’s existing EHR on a zero-footprint dashboard (ECG Viewer).

ECG Viewer is a web based dashboard with a secure and compliant infrastructure that displays a patient’s ECG history and real-time ECG-AI results to support clinical decision making.

ECG-AI Results

Prior standard 12L ECGs and displays results in patient timeline

Integrated With Existing Work Flow

Category III CPT® Codes

Anumana received two Category III CPT® codes from the American Medical Association effective as of January 1 2023.

The approval of these codes is a major milestone for AI in cardiology, recognizing Anumana’s ECG-AI as innovative solutions necessitating the creation of a new procedure category.

Code	Description
+0764T	Assistive algorithmic ECG risk-based assessment from concurrently performed ECGs.
0765T	Assistive algorithmic ECG risk-based assessment from previously performed ECGs.